Tandem Diabetes Care, Inc. (TNDM)
TNDM · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Metabolicsrc
Signal Snapshot
5
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
4
Publications on Record
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial. — Endocrinol Diabetes Metab (2026) PMID 42671087
- Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. — Endocrinol Metab Clin North Am (2026) PMID 42526999
4 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Tandem Diabetes Care, Inc..
Full TNDM Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.